Drug firm Hetero has launched a bloslmllar of Bevaclzumab. used In treating metastatic colorectal cancer (mCRC), under the brand name CIzumabTM'. The product has been approved by Drug Controller General of India (DCGI) and Is recommended as a first-line ... India Infoline, 2 months ago
Hetero launches biosimilar of cancer drug - The Hindu, 2 months ago
Hetero’s biosimilar cancer drug - Business Line, 2 months ago
More from: Money Today, NDTV...and 5 other sources
Mumbai, Jul 31 () Hetero Healthcare, part of the Rs 7,500-crore Hetero Drugs, is setting up three units in Andhra Pradesh, Telangana and Assam to expand its formulation business in the country. "We are setting up three new units at Andhra Pradesh, ...Times of India, 4 weeks ago PTI - HETEROHEALTH(DCM25) - Hetero Healthcare to set up units in three states Namibia Press Agency, 4 weeks ago
Hetero Drugs Ltd. has the launch of a biosimilar for Roche's Avastin® (bevacizumab) in India. Hetero is marketing the drug under the brand name CizumabTM as a treatment for metastatic colorectal cancer. Hetero's launch is the second release of an ...JD Supra, 1 month ago Second Avastin biosimilar launched in India FiercePharma, 1 month ago Hetero launches Avastin biosimilar in India Livemint.com, 2 months ago
In an explosion at Hetero Drugs unit at Nakkapalli in Visakhapatnam, one worker died on the spot and two were seriously injured, on Wednesday evening.The incident happened when the workers were cuttin...The Hindu, 2 months ago
What is Isobutyl formate? It is a colourless liquid used as a flavour and fragrance ingredient because of its sweet and slightly fruity odour. VISAKHAPATNAM: In yet another industrial mishap in Visakhapatnam, one contract worker was killed and ...New Indian Express, 2 months ago One worker killed in explosion at pharma unit The Freepress Journal, 2 months ago Worker killed in explosion at pharma unit Chandigarh Tribune, 2 months ago One killed in explosion at Pharma Unit United News of India, 2 months ago
Hetero Drugs Launches Biosimilar 'Bevacizumab' For The Treatment Of Metastatic Colorectal Cancer (mCRC) Under The Brand Name 'Cizumabtm'
/PRNewswire/ -- Hetero, one of India's leading generic pharmaceutical companies, today announces the launch of Biosimilar 'Bevacizumab' in India for the treatment of metastatic colorectal cancer (mCRC) under the brand name 'CizumabTM' The product ...BioSpace, 2 months ago Hetero launches biosimilar Bevacizumab for cancer India Infoline, 2 months ago Hetero Launches Biosimilar #Bevacizumab# for the Treatment of Metastatic Colorectal Cancer (mCRC) Under the Brand Name #Cizumab(TM)# Newswit.com, 1 month ago Hetero lança 'Bevacizumab' biossimilar para o tratamento de Cncer Colorretal Metastático (mCRC) com o nome de 'CizumabTM' Healthcare Dive, 2 months ago
One of the generic Indian pharmaceutical companies, Hetero Drugs has launched a biosimilar for the treatment of metastatic colorectal cancer (mCRC) in India. Advertisement The drug called as "Bevacizumab" has been approved by the Drug Controller General of ...Med India, 2 months ago
Drug firm Zydus Cadila has inked a generic manufacturing pact with the Medicines Patent Pool for manufacturing global pharma major Bristol-Myers Squibb's daclatasvir tablets used in the treatment of Hepatitis C. Indian pharma firms Aurobindo, ...India Infoline, 1 month ago Lupin, 5 Other Pharma Firms Ink Licensing Pact With Medicines Patent Pool NDTV, 1 month ago 6 Indian pharma cos ink licensing pact with UN-backed MPP Business Standard, 1 month ago Indian pharma cos ink licensing pact with UN-backed MPP The Freepress Journal, 1 month ago
July 27 Vivus Inc * Says lawsuit was filed in response to an abbreviated new drug application filed by Hetero * Vivus Inc says has filed lawsuit in U.S. District court for district of New Jersey against Hetero USA, Inc. and Hetero Labs ...Reuters UK, 1 month ago VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents Stockwatch, 1 month ago VIVUS : Files Lawsuit Against Hetero for Infringement of Stendra Patents 4 Traders, 1 month ago VIVUS INC - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Pharmacy Choice, 3 weeks ago
new generic manufacturing licensing, for antiretrovirals (ARVs) and direct acting anti-viral (DAA) for treating hepatitis C, with seven pharmaceutical companies, six of which are Indian. MPP signed licences with the Hyderabad-based Aurobindo ...Firstpost.com, 1 month ago
on your WebpageAdd Widget >Get your members hooked!